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Background: Creutzfeldt–Jakob disease (CJD) is a rare, rapidly progressive neuro-
degenerative disease that almost always results in death in under a year from onset 
of symptoms. Here, we report four cases of CJD with different clinical presentations 
diagnosed at our institution over a 2-year period.
Cases: The first patient is an 82-year-old woman who presented with depression, 
cognitive decline, and word-finding difficulty over 4  weeks. The patient deteriorated 
neurologically to akinetic mutism and death within 6 weeks of presentation. The second 
patient is a 54-year-old woman with liver cirrhosis who presented with confusion, ataxia, 
and multiple falls over 4 weeks. She was treated initially for hepatic encephalopathy but 
continued to progress to mutism, startle myoclonus, and obtundation. Death occurred 
within 4 weeks of presentation. The third patient is a 58-year-old woman who presented 
with an 8-week history of confusion, urinary incontinence, Parkinsonism, ataxia, and 
myoclonus. Death occurred within 2 months from presentation. The fourth patient is 
a 67-year-old man who presented with a 6-week history of headache, blurred vision, 
ataxia, and personality change and progressed to confusion, myoclonus, akinetic mut-
ism, and obtundation. Death occurred within 3 weeks from presentation.
Conclusion: These four cases highlight the varied possible clinical presentations of CJD 
and demonstrate the importance of considering CJD in patients with atypical presenta-
tions of rapidly progressive cognitive decline. To diagnose CJD, brain biopsy remains the 
gold standard. However, the presence of CSF protein 14-3-3, typical MRI findings and 
suggestive EEG abnormalities, all support the diagnosis.
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INtRoDUCtIoN
Creutzfeldt–Jakob disease (CJD) is a rare neurodegenerative disorder that causes rapidly progressive 
dementia leading to death. It belongs in a group of diseases known as prion diseases. The central 
pathological event of CJD is formation of an abnormally folded protein called scrapie prion protein 
(PrPSc) from the wild-type cellular prion protien PrPC. The PrPSc then acts as a template for more 
PrPC to be improperly folded into PrPSc in a process that is poorly understood. Unlike PrPC, the PrPSc 
is insoluble and cannot be degraded by proteinase enzymes. This substance accumulates and results 
in the pathological changes characteristic of CJD: spongiform changes of gray matter and neuronal 
loss without inflammation (1).
The incidence of CJD in the United States is estimated to be 1–1.5 per million per year (2). The 
age of onset is usually between 55–75 years, median 68 years, and both genders are affected equally. 
taBLe 1 | patient characteristics.
age/sex Clinical presentation Initial diagnosis time from onset 
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MRI findings eeG findings CsF  
14-3-3
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7 weeks Small vessel disease Generalized 
slowing
Positive Positive
54/F Confusion, ataxia, and falls Hepatic 
encephalopathy





58/F Confusion, myoclonus, urinary 
incontinence, ataxia, and Parkinsonism
CJD 10 weeks DWI and FLAIR 
hyperintensity in basal 
ganglia and pulvinar 




67/M Headache, blurred vision, ataxia, 




9 weeks DWI and FLAIR 
hyperintensity in basal 
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There are four subtypes of CJD: sporadic, familial, iatrogenic, 
and variant form (3). Sporadic CJD is the most common form 
of the disease and constitutes about 85–90% of all CJD cases 
(4). Clinical presentation is manifested by rapidly progressive 
cognitive decline and varied associated neuropsychiatric mani-
festations like myoclonus, cerebellar ataxia, visual symptoms, 
pyramidal and extrapyramidal signs, and akinetic mutism. The 
median duration of survival is approximately 4.5 months from 
onset of symptoms, with 90% of patients surviving less than 
1 year (4). Unfortunately, CJD is always fatal. Definite diagnosis of 
CJD requires brain biopsy, which is not always feasible given the 
highly invasive nature of the procedure. Other limitations of brain 
biopsy include concerns of transmission to health care workers 
and reduced diagnostic yield if obtained tissue is insufficient or 
performed on an area of the brain without spongiform changes/
PrPSc deposition (5–7). These factors can make the diagnosis of 
CJD challenging, especially if it presents in an atypical way.
Here, we present four cases that we diagnosed with sporadic 
CJD from June 2014 to March 2016 at St. Louis University 
Hospital in St. Louis, MO, USA. Table 1 summarizes the cases.
Case pReseNtatIoNs
The first patient is an 82-year-old Caucasian woman who pre-
sented with a 4-week history of disorientation, word-finding 
difficulties, and depressed mood. Prior to the onset of these 
symptoms, she lived alone and was completely independent. 
Clinically, she demonstrated fluctuating level of orientation and 
word-finding difficulties. She deteriorated over the course of 
2 weeks and developed apathy, urinary incontinence, and akinetic 
mutism.
Laboratory tests revealed normal vitamin B12, folate, TSH, 
ACE level, ESR, ANA, ANCA, TPO antibodies, and comple-
ments levels. HIV 1 and 2 and RPR returned negative. A 24-h 
EEG showed generalized slowing. Brain MRI revealed chronic 
small vessel ischemic changes. CSF studies demonstrated normal 
protein, glucose, and cell counts. PET CT scan was done to rule 
out occult malignancy and was negative for abnormal uptake. 
CSF paraneoplastic antibodies returned negative.
With more common etiologies of aphasia and rapidly 
progressing dementia now ruled out, CJD became suspected. 
CSF 14-3-3 protein and CSF tau protein were both elevated. 
Brain biopsy was recommended to the family for confirmation 
of CJD but they declined and instead chose supportive care. 
The patient passed away 6 weeks later secondary to pneumonia. 
Autopsy was performed. Her brain was sent to the National 
Prion Disease Pathology Surveillance Center (NPDPSC) in 
Cleveland, OH, USA, which confirmed the diagnosis of CJD 
by detecting PrPSc.
The second patient is a 54-year-old Caucasian woman who 
presented with increasing confusion, ataxia, and multiple falls. 
Her past medical history was significant for type 2 diabetes 
mellitus, non-alcoholic steatohepatitis complicated by liver cir-
rhosis (Child-Pugh A), and depression. Her symptoms started 
insidiously over 1  month and then significantly progressed. In 
the 2 weeks prior to admission, she was not able to walk without 
support and became mute. On clinical exam, she opened her eyes 
spontaneously but did not follow commands. She localized pain. 
Occasional startle myoclonus was also noticed.
Systemic exam showed no evidence of astrexis, ascites, or 
organomegaly. Lab tests including ammonia, liver enzymes, and 
INR were within normal range. Blood count and metabolic panel 
were normal. She was started on lactulose and intravenous thia-
mine for suspected hepatic encephalopathy. Continued workup 
including vitamin B12, TSH, ANA, ANCA, caeruloplasmin, TPO 
antibodies, and ACE level all came normal. HIV 1 and 2 and RPR 
returned negative. Heavy metal screen was negative. CSF studies 
including T. wipplei and ACE level were negative. Autoimmune 
paraneoplastic antibodies were negative from both serum and 
CSF. Brain MRI revealed increased signal intensity in the basal 
ganglia on DWI and FLAIR sequences.
Over the subsequent 2 weeks, her mental status continued to 
worsen. EEG showed generalized periodic sharp wave complexes 
and slow background activity (Figure  1). Given her MRI and 
EEG results, CJD became suspected. Her CSF protein 14-3-3 and 
CSF tau amount were both elevated. Before we could confirm her 
diagnosis with a brain biopsy, she developed respiratory failure 
secondary to aspiration pneumonia and passed away. Autopsy 
was performed. Her brain was sent to NPDPSC, which detected 
PrPSc and confirmed the diagnosis of CJD.
The third patient is a 58-year-old African–American woman 
who presented with 2-month history of rapidly progressive 
FIGURe 1 | eeG of patient 2 with periodic sharp wave complexes circled.
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decline in cognitive function. Two weeks prior to presentation, 
she developed bladder and bowel incontinence. On exam, she 
appeared withdrawn and was oriented to herself and place only. 
She had limb rigidity with bradykinesia and exhibited frequent 
myoclonic jerks of her upper limbs. Finger to nose test showed 
mild ataxia.
Basic labs including TSH, vitamin B12, folate, and ceruloplas-
min levels were within normal. HIV 1 & 2 and RPR came negative. 
Heavy metal and urine toxicology screens were negative. Brain 
MRI showed increased signal intensity within the caudate nuclei, 
putamen, and both pulvinar nuclei of the thalami on DWI and 
FLAIR sequences (Figure 2). EEG showed periodic sharp wave 
complexes.
CSF studies revealed normal protein, glucose, and cell count. 
CSF ACE level was normal and CSF VDRL came negative. A ther-
apeutic trail of Carbidopa–Levodopa was tried for the rigidity 
and bradykinesia, but this did not result in any improvement. 
Paraneoplastic antibody screen came negative; however, CSF 
14-3-3 returned positive. Given strong suspicion of CJD, brain 
biopsy was advised but patient’s family declined it. She  passed 
away 2 months later. Autopsy was not performed due to family 
wishes.
The fourth patient is a 67-year-old Caucasian man who 
presented with a 6-week history of sharp holocranial headache, 
blurred vision, vertigo, imbalance, and personality change. On 
exam, he was lethargic, disoriented, and ataxic. His deep tendon 
reflexes were diffusely exaggerated with bilateral Babinski sign. 
During his hospitalization, he became irritable, agitated, and 
aggressive. He subsequently developed startle myoclonus and 
worsening confusion.
Given his presentation with headaches in addition to mental 
status change, initial diagnostic consideration included subacute 
CNS infection. CT head was negative for acute process. Lumbar 
puncture showed normal CSF cell count and protein. CSF viral, 
bacterial, and fungal infectious workup was negative. HIV and 
RPR were negative. Extensive evaluation for encephalopathy 
yielded; normal metabolic workup, negative systemic infectious 
process, and negative heavy metal and urine toxicology screens. 
TSH, vitamin B12, folate, and ceruloplasmin levels were within 
normal as well as ESR, CRP, and ANA. MRI brain demonstrated 
FIGURe 2 | MRI brain (1. DWI, 2. FLaIR sequence) of patient 3 that demonstrates basal ganglia hyperintense signal.
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mild signal hyperintensity in the basal ganglia and left frontal 
cortex on DWI and FLAIR sequences. Magnetic resonance 
angiography and venography were normal. Patient underwent 
evaluation for occult malignancy with PET CT scan, which did 
not reveal any focus of abnormal uptake. EEG showed general-
ized periodic sharp wave complexes and slow background activ-
ity. CSF paraneoplastic antibodies came negative. CSF 14-3-3 
resulted positive.
The patient’s clinical status deteriorated over the subsequent 
3  weeks to obtundation and akinetic mutism. Patient’s family 
opted for withdrawal of care at this stage. Patient passed away. 
Autopsy was performed and brain tissue was sent to the NPDPSC, 
which confirmed the diagnosis of CJD.
DIsCUssIoN
This case series demonstrates the myriad of possible presenta-
tions of CJD. While our third and fourth patients had a very 
typical presentation, the first two patients presented with clini-
cal syndromes resembling common alternative diagnoses. In 
the diagnostic evaluation of a patient suspected of having CJD, 
it is imperative to first rule out common differential diagnoses, 
some of which are reversible. These include: vascular, toxic, 
metabolic, infectious, vitamin deficiencies, iatrogenic, autoim-
mune, and paraneoplastic etiologies (8). Other neurodegenera-
tive disorders, such as frontotemporal dementia and Alzheimer’s 
disease (AD) must be distinguished from CJD as well.
The first patient presented with a rapidly progressive cognitive 
decline and expressive aphasia at the age of 82 years. Given the 
patient’s advanced age, AD was initially on the patient’s differential 
diagnosis. However, the rapid progression of her symptoms over 
only 4 weeks raised concerns about other possible etiologies such 
as autoimmune encephalitis and CJD. Sporadic CJD typically 
affects patients aged 55–75. It is rarer in patients over 80 years of 
age but has been reported in case reports (9, 10).
Alzheimer’s disease can be differentiated clinically from 
CJD without difficulty, but there are atypical presentations of 
Alzheimer’s dementia that make this more difficult. Rapidly 
progressive Alzheimer’s disease has been well described in the 
literature (11). Van Everbroeck et al. (12) reported the differential 
diagnoses for 201 patients who underwent evaluation with CSF 
14-3-3 for possible CJD, of which 45 patients (22%) had AD as a 
final diagnosis. In another report from Geschwind et al. (8), 5 out 
of 67 non-prion diagnoses of 178 patients presenting with rapidly 
progressive dementia initially suspected of having CJD turned out 
to be AD. Similarly, in a report from the National Prion Center in 
Ohio, 352 out of 1,106 brain autopsies performed for evaluation 
of rapidly progressive dementia were negative for prion disease. 
Alzheimer’s dementia was diagnosed in 154 patients out of these 
352 (43%) (13). Another retrospective study from the Netherlands 
evaluated brain autopsies of patients with probable or possible 
CJD over 11 years. This study found only 146 out of 280 patients 
(52%) had CJD. AD was diagnosed in 40% of the remaining 
autopsies (14). CJD may present with focal cortical symptoms like 
aphasia, which is included in the 2007 UCSF criteria for probable 
CJD (15–17).
Our second patient had a background history of liver cir-
rhosis and, therefore, her initial presentation was suspected 
to be hepatic encephalopathy, for which she was treated with 
lactulose. However, her unresponsiveness to treatment, along 
with her other neurologic deficits such as ataxia prompted 
a search for an alternative diagnosis. The patient received an 
EEG to rule out non-convulsive seizure activity, but it showed 
periodic sharp wave complexes, a finding that hinted to the 
diagnosis of sCJD.
Wieser et al. reported that “the EEG in sCJD shows charac-
teristic changes depending on the stage of the disease, ranging 
from non-specific findings such as diffuse slowing and frontal 
rhythmic delta activity in early stages to disease-typical periodic 
sharp wave complexes in middle and late stages to a reactive coma 
traces or even alpha coma in preterminal EEG recordings” (18).
The diagnostic utility of periodic sharp wave complexes has 
been demonstrated in multiple studies; Steinhoff et al. (19) found 
that periodic sharp wave complexes have a high specificity at 91% 
and a lower sensitivity at 64%. Those figures corresponded to 
a very high positive predictive value of 95%. Hepatic encepha-
lopathy typically results in EEG findings of generalized slowing 
and triphasic waves of the frontal lobes (20). However, periodic 
sharp wave complexes are rather unusual, which helped us to 
think about the diagnosis of CJD in our second patient.




 2. Cerebellar or visual
 3. Pyramidal or extrapyramidal
 4. Akientic mutism
II. tests
 1. Periodic sharp wave complexes in EEG
 2. Protein 14-3-3 detection in CSF (in patients with disease duration of less 
than 2 years)
 3. High signal abnormalities in caudate nucleus and putamen or at least 
two cortical regions (temporal–parietal–occipital) either on DWI or FLAIR 
sequences
Probable CJD: two out of I and at least one out of II.
Possible CJD: two out of I and duration less than 2 years.
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It can be difficult to distinguish hepatic encephalopathy coex-
isting with CJD presentation (21), but another hint that helped 
us make the diagnosis of sCJD in this patient was the brain MRI 
findings. In sCJD, brain MRI may show signal intensity change in 
various cortical regions and/or deep nuclei. Zerr et al. found the 
abnormal pattern of increased signal intensity in the basal ganglia 
and/or ≥2 cortical areas (temporal, parietal, or occipital) on DWI 
or FLAIR sequences in 83% of sCJD patients (23). Our second 
and third patients had typical basal ganglia hyperintensities.
Contrary to the first two patients, our third and fourth 
patients had a rather typical clinical presentation of CJD and 
were diagnosed without difficulty. Both presented with a rap-
idly progressive dementia and suggestive clinical findings of 
ataxia, startle myoclonus, and akinetic mutism in addition to 
visual, pyramidal, and extrapyramidal symptoms, characteristic 
periodic sharp wave complexes on EEG, basal ganglia hyperin-
tensities on brain MRI, and positive CSF 14-3-3, which are all 
typical findings of CJD. The MRI-CJD Consortium criteria for 
diagnosis of sCJD are shown in Table 2 (23).
The median survival time after diagnosis for these four 
patients was 5.3 weeks, which is less than the expected survival 
time of 20 weeks (22). This is because the families of most patients 
opted for palliative care after diagnosis was supported by ancillary 
studies. Another explanation is possibly our patients presented at 
relatively more advantaged stage of the disease. Their cognitive 
decline at onset could have been subtle and went unrecognized 
until more symptoms became obvious.
CoNCLUsIoN
Creutzfeldt–Jakob disease is a fatal neurodegenerative disease 
that presents with rapidly progressive dementia and a wide range 
of neuropsychiatric manifestations. CJD usually results in death 
in less than 1 year after onset. It may present in atypical ways, so 
it is important for physicians to include it in the differential diag-
nosis of patients presenting with a rapidly progressive dementia 
after ruling out common etiologies.
aUtHoR CoNtRIBUtIoNs
AA, JK, and GH were directly involved in the patients’ care. 
AA wrote the initial draft of the manuscript. MM edited the 
manuscript and inserted the tables and figures. AA, GH, and JK 
reviewed and approved the manuscript.
aCKNoWLeDGMeNts
The authors would like to acknowledge the following physicians 
who participated in medical care of the reported cases: Dr. Pratap 
Chand, Dr. Erik Krause, Dr. Fredreck Yap, Dr. Alex Befeler, 
Dr. Elizabeth Strong, and Dr. Jazba Somroo.
ReFeReNCes
1. Prusiner SB, Scott MR, Dearmond SJ, Cohen FE. Prion protein biology. Cell 
(1998) 93:337–48. doi:10.1016/S0092-8674(00)81163-0 
2. Masters CL, Harris JO, Gajdusek DC, Gibbs CJ Jr, Bernoulli C, Asher DM. 
Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the sig-
nificance of familial and sporadic clustering. Ann Neurol (1979) 5:177–88. 
doi:10.1002/ana.410050212 
3. Ladogana A, Puopolo M, Croes EA, Budka H, Jarius C, Collins S, et  al. 
Mortality from Creutzfeldt-Jakob disease and related disorders in Europe, 
Australia, and Canada. Neurology (2005) 64:1586–91. doi:10.1212/01.
WNL.0000160117.56690.B2 
4. Bucelli RC, Ances BM. Diagnosis and evaluation of a patient with rapidly 
progressive dementia. Mo Med (2013) 110(5):422–8. 
5. Jara M, John B, Kreindel S, Wilk-Rivard E, Demaria A Jr. Diagnostic evalua-
tion for Creutzfeldt-Jakob disease in Massachusetts, 1991-2001. Clin Infect Dis 
(2005) 41:829–33. doi:10.1086/432723 
6. Warren JD, Schott JM, Fox NC, Thom M, Revesz T, Holton JL, et  al. 
Brain biopsy in dementia. Brain (2005) 128:2016–25. doi:10.1093/brain/ 
awh543 
7. Jansen GH, Vogelaar CF, Elshof SM. Distribution of cellular prion protein in 
normal human cerebral cortex – does it have relevance to Creutzfeldt-Jakob 
disease? Clin Chem Lab Med (2001) 39:294–8. doi:10.1515/CCLM.2001.045 
8. Geschwind MD, Shu H, Haman A, Sejvar JJ, Miller BL. Rapidly progressive 
dementia. Ann Neurol (2008) 64:97–108. doi:10.1002/ana.21430 
9. de Silva R, Findlay C, Awad I, Harries-Jones R, Knight R, Will R. Creutzfeldt-
Jakob disease in the elderly. Postgrad Med J (1997) 73:557–9. doi:10.1136/
pgmj.73.863.557 
10. Johnson RT, Gonzalez RG, Frosch MP. Case records of the Massachusetts 
General Hospital. Case 27-2005. An 80-year-old man with fatigue, unsteady 
gait, and confusion. N Engl J Med (2005) 353:1042–50. doi:10.1056/
NEJMcpc059024 
11. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly pro-
gressive Alzheimer disease. Arch Neurol (2011) 68:1124–30. doi:10.1001/
archneurol.2011.189 
12. Van Everbroeck B, Dobbeleir I, De Waele M, De Deyn P, Martin JJ, Cras P. 
Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. 
J Neurol (2004) 251(3):298–304. doi:10.1007/s00415-004-0311-9
13. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, et al. 
Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. 
Ann Neurol (2011) 70:437–44. doi:10.1002/ana.22454 
14. Jansen C, Schuur M, Spliet WG, Van Gool WA, Van Duijn CM, Rozemuller 
AJ. [Eleven years of autopsy on account of Creutzfeldt-Jakob disease in the 
Netherlands]. Ned Tijdschr Geneeskd (2009) 153:A172. 
15. Shuttleworth EC, Yates AJ, Paltan-Ortiz JD. Creutzfeldt-Jakob disease pre-
senting as progressive aphasia. J Natl Med Assoc (1985) 77:649–50. 
16. Kobylecki C, Thompson JC, Jones M, Mills SJ, Shaunak S, Ironside JW, et al. 
Sporadic Creutzfeldt-Jakob disease presenting as progressive nonfluent 
aphasia with speech apraxia. Alzheimer Dis Assoc Disord (2013) 27:384–6. 
doi:10.1097/WAD.0b013e318260ab27 
6Al Balushi et al. CJD Case Series
Frontiers in Neurology | www.frontiersin.org August 2016 | Volume 7 | Article 138
17. Riancho J, Delgado-Alvarado M, Fernandez-Torre JL, Sanchez-Juan P, 
Polo  JM. Subacute progressive aphasia: a rare presentation of Creutzfeldt-
Jakob disease. J Neurol (2016) 263:600–2. doi:10.1007/s00415-016-8054-y 
18. Wieser HG, Schindler K, Zumsteg D. EEG in Creutzfeldt-Jakob disease. Clin 
Neurophysiol (2006) 117:935–51. doi:10.1016/j.clinph.2005.12.007
19. Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. 
Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann 
Neurol (2004) 56:702–8. doi:10.1002/ana.20261 
20. Cash WJ, Mcconville P, Mcdermott E, Mccormick PA, Callender ME, 
Mcdougall NI. Current concepts in the assessment and treatment of hepatic 
encephalopathy. QJM (2010) 103:9–16. doi:10.1093/qjmed/hcp152 
21. Camacho-Munoz B, Hernandez-Ramos FJ, Ortega-Martinez De Victoria L. 
[Creutzfeldt Jakob disease and hepatic encephalopathy: coexistence in the 
same patient]. Rev Neurol (2001) 33:540–4. 
22. Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, et  al. 
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human 
transmissible spongiform encephalopathies. Brain (2004) 127:2348–59. 
doi:10.1093/brain/awh249 
23. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, 
et  al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob 
disease. Brain (2009) 132:2659–68. doi:10.1093/brain/awp191 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Al Balushi, Meeks, Hayat and Kafaie. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication 
in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these terms.
